Overview

Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-07-30

Target enrollment:

Participant gender:

Summary

This is an open-label, single-arm, phase I/II trial of immune checkpoint inhibitor combined with pemetrexed intrathecal injection for leptomeningeal metastasis from solid tumors.

Phase:

PHASE1

Details

Lead Sponsor:

Guangzhou Medical University

Treatments:

Pemetrexed
toripalimab